lyell.com (LYEL): Rasio rega marang prakiraan pendapatan

LYEL (Lyell) - tandha merek perusahaan

The change in forward P/S reflects the dynamics of market revenue expectations, with the latest reading standing at 33567.90. Lyell Immunopharma (LYEL) is implementing innovations to protect T-cells from exhaustion in solid tumors. Business growth relies on alliances with oncology centers and pharmaceutical behemoths. Meanwhile, the company strictly adheres to environmental regulations regarding biohazardous waste disposal in its laboratories.

LYEL Lyell: Rasio kapitalisasi pasar marang pendapatan mangsa ngarep ing interval 04.07.2022 - 18.11.2026

Rincian analitis perusahaan Lyell Immunopharma (LYEL)

- rega saham lan target rega konsensus:
Ringkesan analisis perusahaan:lyell.com LYEL
Produk sing diprodhuksi Lyell Pharma

For an investor in Lyell Immunopharma (LYEL), the asset's fundamental value is determined through the lens of the biopharmaceutical sector's defensive potential, which remains independent of macroeconomic fluctuations. The ratio of current market capitalization to expected sales, reflected via the forward P/S trend, enables the rapid identification of market discounts or signs of business degradation, transforming static forecasts into a dynamic tool for risk control and assessing the company's margin of safety.

Analisis pesaing

ImmunityBio Inc - Multiplikator forward rega marang pendapatan|Multiplikator Forward P/S Immunocore Corp IMCR|JANX - Rasio rega marang prakiraan pendapatan|RCUS (arcusbio.com) - Kapitalisasi marang prakiraan pendapatan|Zymeworks Biopharmaceuticals (ZYME) - Rasio rega marang prakiraan pendapatan|Rasio kapitalisasi pasar marang pendapatan mangsa ngarep Tango Pharma (TNGX)|Multiplikator forward rega marang pendapatan IOVA|IMTX - Prakiraan rega marang pendapatan|Multiplikator forward rega marang pendapatan XNCR (Xencor Corp)|Rasio rega marang pendapatan sing dikarepake CMPX|Multiplikator Forward P/S REPL (Replimune)|Rega forward marang dodolan IPHA|Pyxis - Multiplikator Forward P/S|Rasio kapitalisasi pasar marang pendapatan mangsa ngarep Compugen|IO Biotech, Inc. (IOBT) - Rasio rega marang prakiraan pendapatan|Sutro Biopharma, Inc. - Rega forward marang dodolan|INKT (minktherapeutics.com) - Multiplikator Forward P/S|Multiplikator Forward P/S werewolftx.com|Rasio rega marang prakiraan pendapatan immixbio.com (IMMX)|ALXO: Rega mangsa ngarep marang pendapatan|Multiplikator Forward P/S CUE (Cue Biopharma Inc.)|PDS Biotechnology (PDSB) - Rasio kapitalisasi pasar marang pendapatan mangsa ngarep|SONN - Rasio rega marang prakiraan pendapatan|MAIA Biotechnology, Inc. (MAIA) - Multiplikator forward rega marang pendapatan|LIMN: Multiplikator Forward P/S|LAVA Therapeutics N.V. (LVTX) - Multiplikator Forward P/S|Multiplikator forward rega marang pendapatan NXTC|Multiplikator Forward P/S leaptx.com|Multiplikator Forward P/S INTS|Rasio kapitalisasi marang dodolan sing dikarepake Sensei Biotherapeutics, Inc.|Multiplikator Forward P/S TOVX (Theriva Corp)|Rasio kapitalisasi marang dodolan sing dikarepake gritstonebio.com (GRTS)|kinetabio.com - Multiplikator Forward P/S|NexImmune (NEXI) - Multiplikator forward rega marang pendapatan|turnstonebio.com (TSBX) - Rasio rega marang prakiraan pendapatan|Rasio kapitalisasi pasar marang pendapatan mangsa ngarep Vaccinex, Inc (VCNX)|Multiplikator forward rega marang pendapatan HARP